NCT01351623 - Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 9, 2011

Primary Completion Date

January 26, 2016

Study Completion Date

January 26, 2016

Conditions

Multiple Myeloma

Interventions

DRUG

Carfilzomib

Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York